



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/539,672
Filing Date	June 14, 2005
First Named Inventor	Cox et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	1963.02-9527US

Sheet

of

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-4,112,073	09-05-1978	Ono	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		EP 1 585 497 B1	03-26-2008	Intervet International B.V.		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/539,672
Filing Date	June 14, 2005
First Named Inventor	Cox et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	1963.02-9527/US

Sheet

of

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BREITSCHWERDT et al., Prednisolone at Anti-Inflammatory or Immunosuppressive Dosages in Conjunction with Doxycycline Does Not Potentiate the Severity of Rickettsia rickettsii infections in Dogs, Antimicrobial Agents and Chemotherapy, Jan. 1997, pp. 141-47, Vol. 41, No. 1.	
		GELETA et al., Excretion of [ <sup>3</sup> H]prednisolone in clinically normal and experimentally infected bovine udders, Am. J. Vet. Res., August 1984, Vol. 45, No. 8.	
		ORDEN et al., In Vitro Activities of Cephalosporins and Quinolones against Escherichia coli Strains Isolated from Diarrheic Dairy Calves, Antimicrobial Agents and Chemotherapy, March 1999, pp. 510-13, Vol. 43, No. 3.	
		SHPIGEL et al., Efficacy of Cefquinome for Treatment of Cows with Mastitis Experimentally Induced Using Escherichia coli, J. Dairy Sci., pp. 318-25, Vol. 80.	
		MATSUDA et al., Abstract, Combination Chemotherapy for Klebsiella Mastitis, Journal of Veterinary Medicine, Japan, 1995, pp. 985-88, Vol. 48, No. 12.	
		Summary of Product Characteristics of Product CEPHAGUARD LC, marketing authorization of 2001.	
		Report on prednisolone issued by the "Committee for veterinary medicinal products, EMEA/MRL/629/99-FINAL, published in July 1999.	
		Notice of Opposition in French and Notice of Opposition in English for European patent No. 1 585 497 B1.	
		Opposition response dated July 30, 2009.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.